Advertisement
UK markets closed

  • FTSE 100

    7,895.85
    +18.80 (+0.24%)
     

  • FTSE 250

    19,391.30
    -59.37 (-0.31%)
     

  • AIM

    745.67
    +0.38 (+0.05%)
     

  • GBP/EUR

    1.1628
    -0.0055 (-0.47%)
     

  • GBP/USD

    1.2379
    -0.0059 (-0.48%)
     

  • Bitcoin GBP

    51,798.35
    +619.47 (+1.21%)
     

  • CMC Crypto 200

    1,385.98
    +73.36 (+5.59%)
     

  • S&P 500

    4,972.17
    -38.95 (-0.78%)
     

  • DOW

    37,859.09
    +83.71 (+0.22%)
     

  • CRUDE OIL

    83.09
    +0.36 (+0.44%)
     

  • GOLD FUTURES

    2,407.00
    +9.00 (+0.38%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     

  • DAX

    17,737.36
    -100.04 (-0.56%)
     

  • CAC 40

    8,022.41
    -0.85 (-0.01%)
     
Property:

11 beautiful homes with glorious garden rooms

Investing in a home with a garden room will enable you to enjoy your outside space whatever the weather

AstraZeneca sees fall in 2016 earnings as Crestor loss weighs

Reuters - UK Focus

LONDON, Feb 4 (Reuters) - AstraZeneca (NYSE: AZN - news) expects a low to mid single-digit percentage decline in earnings in 2016 as the arrival of cheap generic copies of cholesterol fighter Crestor offsets growth in sales of new medicines, the British-based drugmaker said on Thursday.

Revenue in the fourth quarter of last year fell 5 percent to $6.40 billion, hit by earlier drug patent expiries, generating core earnings per share, which exclude certain items, up 26 percent at 94 cents.

Industry analysts had on average forecast quarterly sales of $6.29 billion and earnings of 95 cents a share, according to Thomson Reuters (Dusseldorf: TOC.DU - news) . (Reporting by Ben Hirschler; editing by David Clarke)